Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
A Randomized Adaptive Phase II/III Study of Buparlisib, a Pan-Class I PI3K Inhibitor, Combined With Paclitaxel for the Treatment of HER2− Advanced Breast Cancer (BELLE-4)Ann. Oncol 2016 Nov 01;[EPub Ahead of Print], M Martín, A Chan, L Dirix, J O'Shaughnessy, R Hegg, A Manikhas, M Shtivelband, P Krivorotko, N Batista López, M Campone, M Ruiz Borrego, QJ Khan, JT Beck, M Ramos Vázquez, P Urban, S Goteti, E Di Tomaso, C Massacesi, S Delaloge
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.